Business Wire

DATAIKU

24.5.2023 11:01:30 CEST | Business Wire | Press release

Share
Dataiku Survey Reveals 84% of Companies Are Using Low- and No-Code Platforms to Achieve AI Goals

According to research run by Dataiku, the platform for Everyday AI, the power of data and AI is becoming increasingly available to non-technical employees at companies across EMEA.

The survey, which was run across the United Kingdom, France, the Netherlands, Germany, and the United Arab Emirates, polled over 700 senior decision makers of companies actively using data science platforms and AI models across the enterprise.

It identified a growing trend of empowered non-technical users working with data and AI to make pivotal business decisions. Forty seven percent of EMEA leaders indicated that their non-technical business users have full access to data and AI to attain business goals, and a further 49% stated that business users have at least some access. Eighty four percent of these companies across EMEA said that they are using low- and no-code platforms to achieve these AI goals.

Dataiku Senior Vice President and General Manager, Gregory Herbert, commented: “We’ve seen a great shift in accessibility via the use of low- and no-code platforms, but for many companies, there’s still extensive untapped potential when it comes to making data and AI available to non-technical business users. What we really want to see is AI that is so ingrained and intertwined with the workings of the day-to-day that it’s just part of the business — not only being used or developed by data scientists. If enterprises want to see a deeper transformation and truly data-driven business results, Everyday AI must become a reality for non-data-focused roles.”

AI Drives Momentum Despite Economic Volatility

The majority of companies (79%) surveyed across EMEA indicated they are leveraging AI to its full capacity, and more than 80% of firms indicated that they are able to measure the ROI of their AI investments.

The survey also indicated continued momentum with AI across EMEA. While leaders indicated that business acceleration (50%) and staying ahead of the competition (36%) were the initial top reasons for investing in AI, 2023 has seen a marked shift in AI business goals. When asked what the top three business goals companies were looking to achieve with AI over the next five years, innovation won out (59%), followed by cost reduction (49%) and increased revenue (48%.)

How Will the European Union’s New AI Regulation Impact Business?

The upcoming EU AI regulation requires that any business that commercialises an AI system as a service or a product on the European market conduct a risk assessment to identify risks for all AI systems across the enterprise. This includes any risk surrounding data quality, transparency, human oversight, and accountability.

While there have been criticisms of the EU AI Act’s potential impact on AI innovation, the survey revealed that nearly 80% of respondents did not feel it would hinder innovation and, rather, would introduce new opportunities.

-ENDS-

About Dataiku

Dataiku is the platform for Everyday AI that allows companies to leverage one central solution to design, deploy, govern, and manage AI and analytics applications. Since its founding in 2013, the company has been the leader in democratizing data and empowering organization-wide collaboration. Today, more than 500 companies worldwide use Dataiku to integrate and streamline their use of data, analytics, and AI, driving diverse use cases from fraud detection and customer churn prevention, to predictive maintenance and supply chain optimization. Stay connected with us on our blog, Twitter (@dataiku) and on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005027/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye